NYSE:BMYPharmaceuticals
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer
Early March, the FDA approved Bristol-Myers Squibb’s Sotyktu for adults with active psoriatic arthritis, the first TYK2 inhibitor cleared for this use following Phase 3 trials.
In a separate early March update, oral mezigdomide showed significant progression free survival benefit in a Phase 3 trial in relapsed or refractory multiple myeloma.
Bristol-Myers Squibb, NYSE:BMY, is adding fresh clinical momentum to a portfolio that already spans immunology and cancer. The stock last closed at...